San Diego-centered Viking Therapeutics marked alone as a serious competitor in the weight loss drug market in February right after revealing promising details from a mid-phase trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when given as a weekly injection As well as in March the company unvei